BPMC Overview
Upcoming Projects (BPMC)
-
Discussing Blueprint Medicines’ FDA Approval of AYVAKIT for treating systemic mastocytosis
Ticker: BPMC
Execute By: Jun 30, 2023
Executed Projects (BPMC)
-
A Third View: Examining the recent data from the PIONEER Trial of Blueprint's AYVAKIT (avapritinib) in treating patients with Indolent Systemic Mastocytosis
Ticker: BPMC
Executed On: Apr 04, 2023 at 11:30 AM EDT -
A Second View: Examining the recent data from the PIONEER Trial of Blueprint's AYVAKIT (avapritinib) in treating patients with Indolent Systemic Mastocytosis
Ticker: BPMC
Executed On: Mar 22, 2023 at 10:30 AM EDT -
Examining the recent data from the PIONEER Trial of Blueprint's AYVAKIT (avapritinib) in treating patients with Indolent Systemic Mastocytosis
Ticker: BPMC
Executed On: Mar 10, 2023 at 02:00 PM EST -
A Second View: Digging into the potential of AYVAKIT (avapritinib) as part of treatment in patients with non advanced systemic mastocytosis
Ticker: BPMC
Executed On: Aug 23, 2022 at 12:00 PM EDT -
Digging into the potential of AYVAKIT (avapritinib) as part of treatment in patients with non advanced systemic mastocytosis
Ticker: BPMC
Executed On: Aug 23, 2022 at 10:00 AM EDT -
Checking on the systemic mastocytosis landscape with a focus on the potential of Ayvakit (avapritinib), BLU-263, and Bezuclastinib (CGT9486/ PLX9486)
Tickers: BPMC, COGT
Executed On: Mar 31, 2022 at 12:00 PM EDT
Expired Projects (BPMC)
-
A 3rd Look - Understanding Disease Management in Systemic Mastocytosis - A Look at Pipeline Products from Blueprint & Deciphera
Tickers: BPMC, DCPH
Execute By: Sep 20, 2018
Upcoming & Overdue Catalysts (BPMC)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (BPMC)
Strategic Initiatives (BPMC)
-
Blueprint Medicines (BPMC) to acquire Lengo Therapeutics for $250M in cash
Ticker: BPMC
Announcement Date: Nov 29, 2021
